Centaurus Therapeutics
London, United Kingdom · Biotechnology, Health Care, Other
Centauri Therapeutics Limited is a UK-based biotechnology company developing novel treatments for life-threatening diseases using its proprietary Alphamer technology. This approach harnesses "programmable immunity" by redirecting natural antibodies to target pathogens, using molecules that bind to pathogens and present epitopes to trigger an immune response. Backed by strong IP and a portfolio of
Key facts
- Headquarters
- London, United Kingdom
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Other
- Status
- Private
- Website
- centauritherapeutics.com
- Company page
Recent activity at Centaurus Therapeutics
- : Centauri Therapeutics raises £6M from AMR Action Fund, extending its Series A round to £30M. The funding will aid Phase I clinical studies for its lead candidate CTX-187.
- : Centauri Therapeutics receives an additional $5.1M grant from CARB-X to advance ABX-01 to clinical trials, bringing total support to $12.3M since 2019.
- : Centauri Therapeutics Appoints Debra Barker as Chief Medical Officer
- : Centaurus Therapeutics, Inc.
- : Centauri Therapeutics Closes £24 Million Gbp Series A Investment Round
Centaurus Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series A | $6.0M |
| Jul 2025 | Grant | $5.1M |
| Jun 2022 | Venture | $2.0M |
| Feb 2022 | Series A | $24.0M |
Leadership
- Jeremy Blitzer, Executive Officer, Director
- Stephen Halasz, Executive Officer, Director
- Jennifer Schneider, Chief Executive Officer
- Debra Barker, Chief Medical Officer
Verified email and direct lines for Centaurus Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to Centaurus Therapeutics
- Compugen · Biotechnology, Health Care, Other, Therapeutics
- Ajax Therapeutics, Inc. · Biotechnology, Health Care, Other, Therapeutics
- Strata Oncology · Biotechnology, Health Care, Other, Therapeutics
- Vor Bio · Biotechnology, Health Care, Other, Therapeutics
- Gallant · Biotechnology, Health Care, Other, Therapeutics
About Centaurus Therapeutics: questions and answers
What does Centaurus Therapeutics do?
Centauri Therapeutics Limited is a UK-based biotechnology company developing novel treatments for life-threatening diseases using its proprietary Alphamer technology. This approach harnesses "programmable immunity" by redirecting natural antibodies to target pathogens, using molecules that bind to pathogens and present epitopes to trigger an immune response. Backed by strong IP and a portfolio of
Where is Centaurus Therapeutics headquartered?
Centaurus Therapeutics is headquartered in London, United Kingdom.
Has Centaurus Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for Centaurus Therapeutics. The most recent, Series A of $6.0M, was in Feb 2026.
Who leads Centaurus Therapeutics?
Jennifer Schneider is a Chief Executive Officer at Centaurus Therapeutics.
What is the latest news on Centaurus Therapeutics?
On Feb 24, 2026, Centauri Therapeutics raises £6M from AMR Action Fund, extending its Series A round to £30M. The funding will aid Phase I clinical studies for its lead candidate CTX-187.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy